Advertisement
News
Subscribe to MDT Magazine News

Parascript Awarded $244,479.25 Affordable Care Act Grant From the U.S. Government

November 8, 2010 3:35 am | by Bio-Medicine.Org | Comments

LONGMONT, Colo., Nov. 8, 2010 /- Parascript, LLC, the image analysis and pattern recognition technology provider, today announced that it was awarded a cash grant of $244,479.25 under the U.S. Government's Affordable Care Act. Under this act, the therapeutic discovery project program...

TOPICS:

Biodel to Present Data from Product Development Programs at 2010 Diabetes Technology Meeting

November 8, 2010 3:34 am | by Bio-Medicine.Org | Comments

DANBURY, Conn., Nov. 8, 2010 /-  Biodel Inc. (Nasdaq: BIOD ) announced today that the following abstracts describing recent findings from the company's product development programs have been accepted for poster presentation at the Tenth Annual Diabetes Technology Meeting in Bethesda,...

TOPICS:

Need Help Affording Your Meds? LegitScript Adds Patient Assistance Feature

November 7, 2010 10:32 pm | by Bio-Medicine.Org | Comments

PORTLAND, Oregon, Nov. 8, 2010 /- A leading Internet pharmacy verification service offers a new message for patients: There are ways to get affordable medicines without using unregulated, potentially dangerous "rogue" Internet pharmacies. LegitScript, a firm that monitors "rogue" Internet...

TOPICS:
Advertisement

WuXi PharmaTech Awarded GLP Certificate from SFDA for Suzhou Toxicology Facility

November 7, 2010 10:32 pm | by Bio-Medicine.Org | Comments

SHANGHAI, Nov. 8, 2010 /PRNewswire-Asia/ -- WuXi PharmaTech (NYSE: WX ), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced that it had been awarded a Certificate of Good...

TOPICS:

Combating Childhood Cancer

November 7, 2010 10:31 pm | by San Diego Business Journal | Comments

Beth Anne Baber believes the intellectual capital, business acumen and philanthropic potential in San Diego provide the ideal environment to support the growth of a new institute that focuses on pediatric cancer research, diagnosis and treatment.

TOPICS:

Chimerix Reaffirms Its Commitment to CMX001 as a Medical Countermeasure for Smallpox and Broad-Spectrum Antiviral Agent

November 7, 2010 8:35 pm | by Bio-Medicine.Org | Comments

RESEARCH TRIANGLE PARK, N.C., Nov. 7, 2010 /- Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today reaffirmed its commitment to the dual development of CMX001 as a medical countermeasure against smallpox and as a broad-spectrum antiviral...

TOPICS:

Harvard's headache cure: LSD?

November 7, 2010 8:34 pm | by Mass High Tech: The Journal of New England Technology | Comments

Move over, Advil. Harvard Medical School researcher John Halpern says LSD, the hallucinogen at the heart of the 1960s drug counterculture, holds a better treatment for cluster headaches, and he's formed a company he hopes will bring to market a drug based on his research.

TOPICS:

In First Phase 3 Trial, Tasocitinib (CP-690,550), an Oral JAK Inhibitor, Administered as Monotherapy, Reduces Signs and Symptoms of Active Rheumatoid Arthritis and Improves Ph...

November 7, 2010 4:33 pm | by Bio-Medicine.Org | Comments

NEW YORK, Nov. 7, 2010 /- Pfizer Inc. (NYSE: PFE ) today announced results of ORAL Solo (1045), a Phase 3 study that showed tasocitinib (CP-690,550), an investigational, novel, oral JAK inhibitor, administered as monotherapy met two primary endpoints, demonstrating a statistically...

TOPICS:
Advertisement

Studying the metabolome of smokers, Lombardi researchers find early signs of damage

November 7, 2010 7:32 am | by EurekAlert | Comments

(Georgetown University Medical Center) Examining the blood "metabolomics" profile of smokers immediately after they had a cigarette revealed activation of pathways involved in cell death, inflammation, and other forms of systemic damage, say researchers at Georgetown Lombardi...

TOPICS:

APHA 2010: Health-care reform and people with disabilities

November 6, 2010 8:33 pm | by EurekAlert | Comments

(Indiana University) Federal health-care reform holds the promise of more independent lives for people with disabilities. While a repeal of the law will be difficult, not funding elements could have the same impact as a repeal, says Heather A. McCabe, J.D., with Indiana...

TOPICS:

Metamark Genetics names Straley as CEO

November 6, 2010 5:33 pm | by Mass High Tech: The Journal of New England Technology | Comments

Molecular diagnostics startup Metamark Genetics Inc. has named Mark Straley as the company's new president, CEO and member of the board of directors. Interim CEO Kenneth Weg, a co-founder of the company, will continue in his role as chairman of the board.

TOPICS:

U.S. Genomics renames to Pathogenetix, raises $1.3M

November 6, 2010 5:33 pm | by Mass High Tech: The Journal of New England Technology | Comments

U.S. Genomics, a pathogen-diagnostic technologies firm in Woburn, has changed its name to Pathogenetix Inc. The name change was noted in a regulatory filing with the U.S. Securities and Exchange Commission, in which the company reported it had raised $1.3 million in an equity offering and...

TOPICS:

Legal wrangling puts rights to diffusion tensor imaging in spotlight

November 6, 2010 5:33 pm | by Diagnostic Imaging | Comments

A California neurosurgeon has launched what could turn into an epic legal battle over the rights to use diffusion tensor imaging, an MR technology that lately has begun to catch on as a diagnostic and neurosurgical planning tool.

TOPICS:

Amgen, Pfizer, and World-Class Professional Golfer Phil Mickelson Announce Partnership

November 6, 2010 5:32 pm | by Bio-Medicine.Org | Comments

THOUSAND OAKS, Calif., and COLLEGEVILLE, Pa., Nov. 6, 2010 /- Amgen Inc. (Nasdaq: AMGN ), Pfizer Inc. (NYSE: PFE ) and world-class professional golfer Phil Mickelson, have entered into a partnership to share Phil's experience with his diagnosis of psoriatic arthritis and treatment with...

TOPICS:

Major clinical trial prompts call for change to treatment guidelines for severe malaria worldwide

November 6, 2010 9:36 am | by EurekAlert | Comments

(Wellcome Trust) The largest ever clinical trial in patients hospitalized with severe malaria has concluded that the drug artesunate should now be the preferred treatment for the disease in both children and adults everywhere in the world. The study, funded by the Wellcome Trust,...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading